Crispr Therapeutics led gene-editing stocks lower after new studies published by Nature Medicine found that cells whose genomes are edited with the CRISPR-Cas9 technology have the potential to cause cancer, Stat News reports. Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn — a potential game-changer for the companies developing CRISPR-based therapies. [Full article]